The Wroclaw-based biotechnology company has become the first in the world to transport the peptides liraglutide and semaglutide through the skin. The last is a substance used in drugs such as the record-breaking Ozempic and Wegovy from the Danish company NovoNordisk.
Transdermally delivered substances belong to the group of glucagon-like peptide-1 (GLP-1) analogs used to treat a variety of medical conditions, including diabetes, insulin resistance and obesity. Biott’s patented MTC-Y transdermal technology is expected to help make these substances more convenient to use, while maintaining treatment efficacy and reducing side effects. Importantly, the Wroclaw-based company’s preparation delivers semaglutide to the body in a stable manner, which also improves treatment comfort.
Biott’s transdermal system can be used to deliver commonly used anti-diabetic, oncology, anti-inflammatory or analgesic drugs. The company plans to conduct the first human clinical trials with semaglutide in 2024. Meanwhile, the results of the Phase 1A clinical trial with dapagliflozin are expected any day now. The first phase of the clinical trial is primarily designed to confirm the efficacy and safety of the MTC-Y carrier.
According to Reuters, industry analysts predict that the market for semaglutide and similar drugs will reach annual sales of $100 billion this decade. The market for transdermal drug delivery systems will be worth $8.7 billion by 2027, with a compound annual growth rate (CAGR) of 6.39% from 2021 to 2027.